URMC / Labs / Beck Lab / Publications Recent Publications Ryan Wolf JChen AWieser JJohnson BBaughman LLee GPope EFranco ALove TBeck LA Improved patient- and caregiver-reported outcomes distinguish tacrolimus 0.03% from crisaborole in children with atopic dermatitis.; Journal of the European Academy of Dermatology and Venereology : JEADV. 2024 Feb 15. Stolarczyk APerez-Nazario NKnowlden SAChinchilli EGrier APaller AGill SRDe Benedetto AYoshida TBeck LA Bleach baths enhance skin barrier, reduce itch but do not normalize skin dysbiosis in atopic dermatitis.; Archives of dermatological research. 2023 Sep 27. Moran MCBrewer MGSchlievert PMBeck LA S. aureus virulence factors decrease epithelial barrier function and increase susceptibility to viral infection.; Microbiology spectrum. 2023 Sep 22. Moran MCKlose AYoshida TDe Benedetto ASchneider LCOng PYSimpson ELLeung DYMMiller BLSeplaki CLBeck LA History of S. aureus Skin Infection Significantly Associates with History of Eczema Herpeticum in Patients with Atopic Dermatitis.; Dermatology and therapy. 2023 Aug 24. Guttman-Yassky ESilverberg JIThaçi DPapp KAStänder SBeck LAKim BSHu XLiu JCalimlim BMVigna NCrowley JTTeixeira HDThyssen JP Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: results from a phase 2b, randomized, controlled trial.; Journal of the European Academy of Dermatology and Venereology : JEADV. 2023 Aug 01. Reich KSilverberg JIPapp KADeleuran MKatoh NStrober BBeck LAde Bruin-Weller MWerfel TZhang FBiswas PDiBonaventura MDChan GJohnson SFarooqui SAKerkmann UClibborn C Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.; Journal of the European Academy of Dermatology and Venereology : JEADV. 2023 Jun 19. Reich KSilverberg JIPapp KADeleuran MKatoh NStrober BBeck LAde Bruin-Weller MWerfel TZhang FBiswas PDiBonaventura MDChan GFarooqui SAKerkmann UClibborn C Abrocitinib effect on patient-reported outcomes in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.; Journal of the European Academy of Dermatology and Venereology : JEADV. 2023 Jun 15. Simpson ELSchlievert PMYoshida TLussier SBoguniewicz MHata TFuxench ZDe Benedetto AOng PYKo JCalatroni ARudman Spergel AKPlaut MQuataert SAKilgore SHPeterson LGill ALDavid GMosmann TGill SRLeung DYMBeck LA Rapid Reduction in Staphylococcus aureus in Atopic Dermatitis Subjects Following Dupilumab Treatment.; The Journal of allergy and clinical immunology. 2023 Jun 12. Guttman-Yassky EBahadori LBrooks LClark KLGrindebacke HHo CNKatial RPham THWalton CDatto CJ Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial.; Journal of the European Academy of Dermatology and Venereology : JEADV; Vol 37(10), pp. e1211-e1214. 2023 Jun 12. Arnold KAPeterson LFBeck LABrewer MG JAK Signaling Is Critically Important in Cytokine-Induced Viral Susceptibility of Keratinocytes.; International journal of molecular sciences; Vol 24(11). 2023 May 25. Simpson ELDe Benedetto ABoguniewicz MOng PYLussier SVillarreal MSchneider LCPaller ASGuttman-Yassky EHanifin JMSpergel JMBarnes KCDavid GAustin BLeung DYMBeck LA Phenotypic and Endotypic Determinants of Atopic Dermatitis Severity from the ADRN Registry.; The journal of allergy and clinical immunology. In practice. 2023 May 12. Moran MCChinchilli EKenney HMPope EMScott GBrewer MGBeck LA Stage of Keratinocyte Differentiation is a Key Determinant of Viral Susceptibility in Human Skin.; The Journal of investigative dermatology. 2023 Mar 28. Zuberbier TBeck LABedbrook Ade Bruin-Weller MBousquet JCork MDouladiris NKatoh NMortz CGWerfel TWojciech FWollenberg ASiemens KStevanovic KWorm M Developing integrated care pathways for atopic dermatitis-Challenges and unmet needs.; Clinical and translational allergy; Vol 13(3), pp. e12236. 2023 Mar. Smith HDWilliams BBeck LADe Benedetto A Erythema Multiforme Secondary to Poison Ivy Contact Dermatitis.; Dermatitis : contact, atopic, occupational, drug. 2023 Feb 27. Yang BWilkie HDas MTimilshina MBainter WWoods BDaya MBoorgula MPMathias RALai PPetty CRWeller EHarb HLeung DYMBeck LASimpson ELHata TRBarnes KCPhipatanakul WLeyva-Castillo JMGeha RS The IL-4Rα Q576R polymorphism is associated with increased severity of atopic dermatitis and exaggerates allergic skin inflammation in mice.; The Journal of allergy and clinical immunology. 2023 Jan 20. Bissonnette RSimpson EEichenfield LFGuttman-Yassky ESilverberg JIBeck LAMija LThyssen JPBieber TKabashima KSiegfried EStingl Gvan de Kerkhof PYosipovitch GPaul CPaller AS The vIGA-AD scale for atopic dermatitis: uptake in the past five years and position of the International Eczema Council.; Journal of the European Academy of Dermatology and Venereology : JEADV. 2023 Jan 09. Schlievert PMKilgore SHBeck LAYoshida TKlingelhutz AJLeung DYM Host Cationic Antimicrobial Molecules Inhibit S. aureus Exotoxin Production.; mSphere. 2023 Jan 04. Moran MCPope EMBrewer MGBeck LA Supply Chain Disruptions During COVID Pandemic Uncover Differences in Keratinocyte Culture Media.; JID innovations : skin science from molecules to population health. 2022 Aug 22. Paller ASBeck LA Bleach baths for atopic dermatitis: Evidence of efficacy but more data are needed.; Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology; Vol 128(6). 2022 Jun. Beck LADeleuran MBissonnette Rde Bruin-Weller MGalus RNakahara TSeo SJKhokhar FAVakil JXiao JMarco ARLevit NAO'Malley JTShabbir A Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.; American journal of clinical dermatology. 2022 May 03. Beck LACork MJAmagai MDe Benedetto AKabashima KHamilton JDRossi AB Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis.; JID innovations : skin science from molecules to population health; Vol 2(5), pp. 100131. 2022 Apr 26. Brewer MGMonticelli SRMoran MCMiller BLBeck LAWard BM Conditions That Simulate the Environment of Atopic Dermatitis Enhance Susceptibility of Human Keratinocytes to Vaccinia Virus.; Cells; Vol 11(8). 2022 Apr 14. Pope EMLaageide LBeck LA Management of Allergic Skin Disorders in Pregnancy.; Immunology and allergy clinics of North America; Vol 43(1), pp. 117-132. 2022 Jan 28. Paller ASBeck LABlauvelt ASiegfried ECCork MJWollenberg AChen ZKhokhar FAVakil JZhang ABansal ACyr SL Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis-A pooled analysis of trial data.; Pediatric dermatology. 2022 Jan 26. Beck LAPesonen MThakar JGeoras SNJärvinen KM IgE Sensitization Drives the Atopic March.; American journal of respiratory and critical care medicine. 2022 Jan 08. Beck LABieber TWeidinger STauber MSaeki HIrvine ADEichenfield LFWerfel TArlert PJiang LRøpke MPaller AS Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: analysis of microbial diversity in ECZTRA 1, a randomized controlled trial.; Journal of the American Academy of Dermatology. 2022 Jan 03. Herman KEYoshida THughson AGrier AGill SRBeck LAFowell DJ IL-17-Dependent Dysregulated Cutaneous Immune Homeostasis in the Absence of the Wiskott-Aldrich Syndrome Protein.; Frontiers in immunology; Vol 13. 2022. Yoshida TBeck LADe Benedetto A Skin barrier defects in atopic dermatitis: From old idea to new opportunity.; Allergology international : official journal of the Japanese Society of Allergology. 2021 Dec 13. Tuttle KLForman JBeck LA Novel systemic treatments in atopic dermatitis: Are there sex differences?; International journal of women's dermatology; Vol 7(5Part A). 2021 Dec. Wollenberg ABeck LAde Bruin Weller MSimpson ELImafuku SBoguniewicz MZachariae ROlsen CKThyssen JP Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials.; The British journal of dermatology. 2021 Oct 12. Daya MCox CAcevedo NBoorgula MPCampbell MChavan SCho MHDavid GLKachroo PLasky-Su JLi XMcHugh CPQiao DRafaels NBeck LABleecker ERCaraballo LCupples ALFigueiredo CAGallo RLHanifin JHansel NNHata TRHersh CPKnight-Madden JLeung DYMGuttman-Yassky EMeyers DAO'Connor GOber COng PYOrtega VEPaller ASPutcha NReed RMSchneider LCSilverman EKSlifka MKSpergel JMVasan RSViaud-Martinez KAWatson HWeiss STRuczinski IBeaty THMathias RABarnes KC Multi-ethnic genome-wide and HLA association study of total serum IgE.; The Journal of allergy and clinical immunology. 2021 Sep 15. Arehart CHDaya MCampbell MBoorgula MPRafaels NChavan SDavid GHanifin JSlifka MKGallo RLHata TSchneider LCPaller ASOng PYSpergel JMGuttman-Yassky ELeung DYMBeck LAGignoux CRMathias RABarnes KC Polygenic prediction of atopic dermatitis improves with atopic training and filaggrin factors.; The Journal of allergy and clinical immunology. 2021 Jun 07. Moran MCPandya RPLeffler KAYoshida TBeck LABrewer MG Characterization of Human Keratinocyte Cell Lines for Barrier Studies.; JID innovations; Vol 1(2). 2021 Jun. Siegfried ECBieber TSimpson ELPaller ASBeck LABoguniewicz MSchneider LCKhokhar FAChen ZPrescilla RMina-Osorio PBansal A Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial.; American journal of clinical dermatology. 2021 Mar 03. Mahadevan NChristakis YDi JBruno JZhang YDorsey ERPigeon WRBeck LAThomas KLiu YWicker MBrooks CKabiri NSBhangu JNorthcott CPatel S Development of digital measures for nighttime scratch and sleep using wrist-worn wearable devices.; NPJ digital medicine; Vol 4(1). 2021 Mar 03. Beck LAThaçi DDeleuran Mde Bruin-Weller MChen ZKhokhar FAZhang MOzturk ZEShumel B Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study.; The Journal of dermatological treatment. 2021 Feb 08. Bin LMalley CTaylor PPreethiBoorgula MChavan SDaya MMathias MShankar GRafaels NVergara CPotee JCampbell MHanifin JMSimpson ESchneider LCGallo RLHata TPaller ASDe Benedetto ABeck LAOng PYGuttman-Yassky ERichers BBaraghoshi DRuczinski IBarnes KLeung DYMMathias RA Whole genome sequencing identifies novel genetic mutations in patients with eczema herpeticum.; Allergy. 2021 Feb 06. Boguniewicz MBeck LASher LGuttman-Yassky EThaçi DBlauvelt AWorm MCorren JSoong WLio PRossi ABLu YChao JEckert LGadkari AHultsch TRuddy MMannent LPGraham NMHPirozzi GChen ZArdeleanu M Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis.; The journal of allergy and clinical immunology. In practice. 2021 Jan 13. Bawany FNorthcott CABeck LAPigeon WR Sleep Disturbances and Atopic Dermatitis: Relationships, Methods for Assessment, and Therapies.; The journal of allergy and clinical immunology. In practice. 2020 Dec 12. Bawany FFranco AIBeck LA Dupilumab: One therapy to treat multiple atopic diseases.; JAAD case reports; Vol 6(11). 2020 Nov. Beck LASilverberg JISimpson ELYosipovitch GEckert LGuillemin IChen ZArdeleanu MPlaum SGraham NRuddy MPirozzi GGadkari A Dupilumab Significantly Improves Sleep Outcomes in Adult Patients with Atopic Dermatitis: Results from Five Randomized Clinical Trials.; Journal of the European Academy of Dermatology and Venereology : JEADV. 2020 Aug 12. Paller ASSiegfried ECThaçi DWollenberg ACork MJArkwright PDGooderham MBeck LABoguniewicz MSher LWeisman JO'Malley JTPatel NHardin MGraham NMHRuddy MSun XDavis JDKamal MAKhokhar FAWeinreich DMYancopoulos GDBeazley BBansal AShumel B Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial.; Journal of the American Academy of Dermatology. 2020 Jun 20. Beck LAThaçi DDeleuran MBlauvelt ABissonnette Rde Bruin-Weller MHide MSher LHussain IChen ZKhokhar FABeazley BRuddy MPatel NGraham NMHArdeleanu MShumel B Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.; American journal of clinical dermatology. 2020 Jun 17. Wollenberg ABeck LABlauvelt ASimpson ELChen ZChen QShumel BKhokhar FAHultsch TRizova ERossi ABGraham NMHPirozzi GLu YArdeleanu M Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitis.; The British journal of dermatology; Vol 182(6). 2020 Jun. Moran MCBeck LARichardson CT A Spectrum of Skin Disease: How Staphylococcus aureus Colonization, Barrier Dysfunction, and Cytokines Shape the Skin.; The Journal of investigative dermatology; Vol 140(5). 2020 May. Simpson EBissonnette REichenfield LFGuttman EKing BSilverberg JIBeck LABieber TReich KKabashima KSeyger MSiegfried EStingl GFeldman SRMenter Avan de Kerkhof PYosipovitch GPaul CMartel PDubost-Brama AArmstrong JChavda RFrey SJoubert YMilutinovic MParneix ATeixeira HDLin CYSun LKlekotka PNickoloff BDutronc YMallbris LJanes JMDeLozier AMNunes FPaller AS The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.; Journal of the American Academy of Dermatology. 2020 Apr 25. Wieser JKKuehn GJPrezzano JCCusick EHStiegler JDScott GALiesveld JLBeck LA Improvement in a patient with hypereosinophilic syndrome after initiation of dupilumab treatment.; JAAD case reports; Vol 6(4). 2020 Apr. Platts-Mills TAECommins SPBiedermann Tvan Hage MLevin MBeck LADiuk-Wasser MJappe UApostolovic DMinnicozzi MPlaut MWilson JM On the cause and consequences of IgE to galactose-α-1,3-galactose: A report from the National Institute of Allergy and Infectious Diseases Workshop on Understanding IgE-Mediated Mammalian Meat Allergy.; The Journal of allergy and clinical immunology; Vol 145(4). 2020 Apr. Bawany FBeck LAJärvinen KM Halting the March: Primary Prevention of Atopic Dermatitis and Food Allergies.; The journal of allergy and clinical immunology. In practice; Vol 8(3). 2020 Mar. Guttman-Yassky EThaçi DPangan ALHong HCPapp KAReich KBeck LAMohamed MFOthman AAAnderson JKGu YTeixeira HDSilverberg JI Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.; The Journal of allergy and clinical immunology; Vol 145(3). 2020 Mar.